Cart
sales@molnova.com
Home - Products - Angiogenesis - CDK - CYC065

CYC065

CAS No. 1070790-89-4

CYC065 ( CYC-065;CYC 065 )

Catalog No. M10291 CAS No. 1070790-89-4

CYC065 is a derivative of seliciclib and second generation CDK inhibitor that is mainly active on CDK2/5/9.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 155 Get Quote
10MG 282 Get Quote
25MG 480 Get Quote
50MG 691 Get Quote
100MG 972 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote
Group Booking Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    CYC065
  • Note
    Research use only, not for human use.
  • Brief Description
    CYC065 is a derivative of seliciclib and second generation CDK inhibitor that is mainly active on CDK2/5/9.
  • Description
    CYC065 is a derivative of seliciclib and second generation CDK inhibitor that is mainly active on CDK2/5/9; demonstrates cytotoxicity both in MM cell lines sensitive as well as resistant to conventional chemotherapy with IC50 of 0.06-2 uM; blocks cells in the G1 phase and inhibits cell growth specifically in CCNE1-overexpressing USCs; significantly reduces tumour growth in xenografts derived from CCNE1-amplified USCs, shows synergistic effect in vitro and in vivo combined with Taselisib .Brain Cancer Phase 1 Clinical
  • Synonyms
    CYC-065;CYC 065
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    Cancer
  • Indication
    Brain Cancer

Chemical Information

  • CAS Number
    1070790-89-4
  • Formula Weight
    397.53
  • Molecular Formula
    C21H31N7O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : ≥ 100 mg/mL251.56 mM
  • SMILES
    CCC(C(C)O)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CN=C(C=C3C)C
  • Chemical Name
    (2R,3S)-3-[[6-[(4,6-dimethylpyridin-3-yl)methylamino]-9-propan-2-ylpurin-2-yl]amino]pentan-2-ol

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Cocco E, et al. Br J Cancer. 2016 Jul 26;115(3):303-11.
2. Kawakami M, et al. J Natl Cancer Inst. 2017 Jun 1;109(6).
3. Thomas AL, et al. Cell Cycle. 2017 Aug 3;16(15):1453-1464.
4. Rao SS, et al. Oncotarget. 2017 Aug 10;8(48):83925-83939.
Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • M2I-1

    The first small molecule Mad2 inhibitor that targets the binding of Mad2 to Cdc20; equally potent in inhibiting the binding of F-Mbp1 to Mad2.

  • Palbociclib hydrochl...

    A potent and selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM; no inhibition for CDK2A (IC50>5 uM); inhibits MDA-MB453 cells with IC50 of 0.16 uM.

  • CDK5 inhibitor 20-22...

    CDK5 inhibitor 20-223 (CP 668863) potent, selective, ATP-competitive CDK2/5 inhibitor with IC50 of 6.0 and 8.8 nM for CDK2/CyclinE and CDK5/p35, with little to no activity against CDK1/4/6/7/9.

Sign In Join Free